Soleo Health is now a limited distribution partner for the cardiovascular drug LEQVIO®, manufactured by Novartis.
LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
LEQVIO is a subcutaneous injection that Soleo Health will administer to patients in their homes or at one of the Company’s Ambulatory Infusion Centers (AICs) nationwide.
Concurrent with the administration of LEQVIO, Soleo Health will leverage its proprietary clinical outcomes program, SoleMetrics®, to collect and produce valuable real-world data over time for those patients prescribed LEQVIO. SoleMetrics will gather intelligent outcomes from patients throughout their journeys while on LEQVIO to deliver clinical and economic value to key stakeholders.
“Soleo Health’s expertise in caring for patients with complex conditions and our ability to offer services in the home or alternate sites of care creates additional value for pharmaceutical manufacturers. We continue to expand our limited distribution partnerships with numerous drug manufacturers as they appreciate our dedication to clinical excellence and high-quality care,” stated Drew Walk, Soleo Health chief executive officer.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!